Busuttil Ronald W, Lake John R
Division of Liver and Pancreas Transplant, Department of Surgery, UCLA School of Medicine, Los Angeles, CA, USA.
Transplantation. 2004 May 15;77(9 Suppl):S44-51. doi: 10.1097/01.tp.0000126927.49589.3f.
Once regarded as a last-resort therapy for patients with end-stage liver disease, liver transplantation has become a viable therapeutic option because of sweeping improvements in surgical techniques and the development of more powerful immunosuppressive agents. The addition of tacrolimus to the immunosuppression regimen represents a highly potent therapy and a powerful defense against acute rejection. In the decade since tacrolimus was approved for use in the United States, it has become a widely used immunosuppressant in the field of liver transplantation.
肝移植曾经被视为终末期肝病患者的一种最后手段疗法，但由于手术技术的全面改进以及更强大免疫抑制剂的研发，它已成为一种可行的治疗选择。在免疫抑制方案中加入他克莫司是一种高效疗法，也是抵御急性排斥反应的有力手段。自他克莫司在美国获批使用的十年间，它已成为肝移植领域广泛使用的免疫抑制剂。
